Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study
Our findings suggest a causal effect of <i>FCGR3B</i> on AD risk, but not for the remainder of the analyzed DMARD targets. Further research is recommended to elucidate the causal role of <i>FCGR3B</i> in AD and build upon the current literature on viable AD therapeutic targets.
Authors
- Neil M Davies (ORCID: https://orcid.org/0000-0002-2460-0508)
- Christina N. Kushnir
- Victoria Taylor-Bateman
- Emma L. Anderson
Institutions
- Norwegian University of Science and Technology (NO)
- University College London (GB)
Publication Details
- Journal
- Brain Behavior & Immunity - Health
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1016/j.bbih.2026.101185
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00